ArticleThe Journal of experimental medicine1996
CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.Journal of Korean medical science · 2004Trial
- Internal regulation between constitutively expressed T cell co-inhibitory receptors BTLA and CD5 and tolerance in recent thymic emigrants.Open biology · 2024Article
- TLR induces reorganization of the IgM-BCR complex regulating murine B-1 cell responses to infections.eLife · 2019Article
- A unique bone marrow lymphoma patient presenting with an isolated mass: A case report.Oncology letters · 2018Article
- A ligand for CD5 is CD5.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Evolution of the CD163 family and its relationship to the bovine gamma delta T cell co-receptor WC1.BMC evolutionary biology · 2010Article
- Characterization of rabbit CD5 isoforms.Molecular immunology · 2009Article
- Use of flow cytometry to develop and characterize a set of monoclonal antibodies specific for rabbit leukocyte differentiation molecules.Journal of veterinary science · 2008Article
- Positive selection of the peripheral B cell repertoire in gut-associated lymphoid tissues.The Journal of experimental medicine · 2005Article
- Article
- CD5, an important regulator of lymphocyte selection and immune tolerance.Immunologic research · 2002Review
- CD5 (OKT1) augments CD3-mediated intracellular signaling events in human T lymphocytes.Inflammation · 2001Article
- The regulation of CD5 expression in murine T cells.BMC molecular biology · 2001Article
- CD5-positive and CD5-negative human B cells converge to an indistinguishable population on signalling through B-cell receptors and CD40.Immunology · 2000Article
- Activation of bovine B cells via surface immunoglobulin M cross-linking or CD40 ligation results in different B-cell phenotypes.Immunology · 2000Article
- Molecular cloning, genomic organization and cell-binding characteristics of mouse Spalpha.Immunology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In rabbits nearly all B lymphocytes express the glycoprotein CD5, in contrast to mice and humans, where only a small proportion of B cells express this molecule (Raman, C., and K.L. Knight. 1992. J. Immunol. 149:3858-3864). CD5+ B cells appear to develop early in ontogeny and be maintained throughout life by self-renewal. The function of CD5 on B cells is still unknown. We showed earlier that "positive" selection occurs during B lymphocyte development in the rabbit appendix. This selection favors B cell expressing surface immunoglobulins with VHa2 structures in the first and third framework regions (Pospisil, R., G.O. Young-Cooper, and R.G. Mage. 1995. Proc. Natl. Acad. Sci. USA. 92:6961-6965). Here we report that F(ab')2 fragments, especially those bearing VHa2 framework region determinants, specifically interact with the B cell-surface glycoprotein CD5. This interaction can be inhibited by anti-CD5 antibodies. Furthermore, immobilized F(ab')2 fragments selectively bind CD5 molecules in appendix cell lysates. Interactions of VH framework region structures with CD5 may affect maintenance and selective expansion of particular B cells and thus contribute to autostimulatory growth of autoimmune or transformed cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.